AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
BioSpace » Biotechnology
by
1d ago
AAVantgarde Bio announced the presentation of the clinical trial design of the Company’s lead program in Usher 1B by the program’s Principal Investigator, Prof. Francesca Simonelli, at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit, being held today in Seattle ..read more
Visit website
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
BioSpace » Biotechnology
by
1d ago
Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live ..read more
Visit website
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
BioSpace » Biotechnology
by
1d ago
Eupraxia Pharmaceuticals Inc. announced the formation of a Clinical Advisory Board for its gastrointestinal program ..read more
Visit website
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
BioSpace » Biotechnology
by
1d ago
Shattuck Labs, Inc. reported financial results for the quarter ended March 31, 2024 and provided recent business highlights ..read more
Visit website
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
BioSpace » Biotechnology
by
1d ago
Pluri Inc., a leading biotechnology company that transforms cells into solutions, launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective treatments ..read more
Visit website
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
BioSpace » Biotechnology
by
1d ago
Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided business highlights and updates on its pipeline of protein degraders ..read more
Visit website
Astellas Inks Second CAR-T Agreement with Poseida to Develop ‘Convertible’ Cancer Therapies
BioSpace » Biotechnology
by
1d ago
Astellas Pharma and Poseida Therapeutics have entered into a second CAR-T contract to develop novel and flexible allogeneic cell therapies in oncology ..read more
Visit website
FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
BioSpace » Biotechnology
by
1d ago
Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug ..read more
Visit website
Moderna Walks Away from Potential $3B Gene Editing Deal with Metagenomi
BioSpace » Biotechnology
by
1d ago
Citing a strategic prioritization by Moderna, Metagenomi announced Wednesday that the partners have “mutually agreed” to terminate their gene editing agreement ..read more
Visit website
Regeneron Misses Q1 Earnings on Lower-Than-Expected Eylea Sales
BioSpace » Biotechnology
by
1d ago
Regeneron Pharmaceuticals on Thursday reported $1.4 billion in sales of its blockbuster eye drug in the first quarter of 2024, falling short of Wall Street’s expectations of $1.86 billion ..read more
Visit website

Follow BioSpace » Biotechnology on FeedSpot

Continue with Google
Continue with Apple
OR